Vertex Pharmaceuticals Inc
F:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
F:VX1
|
US |
|
B
|
Brunswick Corp
F:BWI
|
US |
|
E
|
Estee Lauder Companies Inc
DUS:ELAA
|
US |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
CH |
|
B
|
Base Resources Ltd
OTC:BSRUF
|
AU |
|
R
|
Republic Services Inc
F:RPU
|
US |
|
Microchip Technology Inc
NASDAQ:MCHP
|
US |
|
Mediobanca Banca di Credito Finanziario SpA
MIL:MB
|
IT |
|
C
|
Continental AG
XHAM:CON
|
DE |
|
M
|
Mckesson Corp
XMUN:MCK
|
US |
|
B
|
Basf Se
DUS:BAS
|
DE |
|
D
|
Dollar General Corp
XMUN:7DG
|
US |
|
S
|
Santam Ltd
JSE:SNT
|
ZA |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 460.99 EUR with a low forecast of 274.98 EUR and a high forecast of 555.28 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
460.99
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 460.99 EUR with a low forecast of 274.98 EUR and a high forecast of 555.28 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 8 years is 15%.
